版本:
中国

BRIEF-uniQure to not seek Glybera marketing authorization renewal in Europe

April 20 uniQure NV:

* uniQure announces it will not seek marketing authorization renewal for Glybera in Europe

* Company maintains focus on core programs in Hemophilia B, Huntington's Disease and congestive heart failure

* Marketing authorization for Glybera to expire on October 25, 2017

* Glybera's usage has been extremely limited and do not envision patient demand increasing materially in years ahead

* uniQure - as a result of withdrawal of Glybera, expects to reduce future expenses related to product by about $2 million annually, beginning in 2018

* Continues to expect its existing cash resources will be sufficient to fund operations into 2019 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐